Literature DB >> 10523220

Partial-liver transplantation to treat familial amyloid polyneuropathy: follow-up of 11 patients.

Y Takei1, S Ikeda, Y Hashikura, T Ikegami, S Kawasaki.   

Abstract

BACKGROUND: Recently, liver transplantation has been used to treat patients with familial amyloid polyneuropathy (FAP).
OBJECTIVE: To describe the clinical course of patients with FAP who received partial-liver transplantation from living donors.
DESIGN: Case series.
SETTING: University hospital in Matsumoto, Japan. PATIENTS: 11 patients with FAP who underwent partial-liver transplantation. The transthyretin gene abnormality in all 11 patients was the substitution of methionine for valine at position 30. INTERVENTION: Partial liver transplantation from living donors. MEASUREMENTS: Preoperative and follow-up (3 to 64 months) clinical data, including routine laboratory data, nerve conduction velocity tests, and sural nerve histology.
RESULTS: All 7 patients who had severe gastrointestinal autonomic disorders or polyneuropathy localized to the lower limbs for less than 4 years showed improvement. Three of 4 patients with polyneuropathy involving both the upper and lower limbs had adverse outcomes, including two deaths. The preoperative duration of their illness was more than 6 years. These 3 patients also had marked decreases in creatinine clearance and nerve conduction velocities and severe loss of myelinated fibers in sural nerves.
CONCLUSION: Preoperative clinical severity and duration of illness are associated with outcomes after liver transplantation for FAP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10523220     DOI: 10.7326/0003-4819-131-8-199910190-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  6 in total

1.  Ten-year follow-up of peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation.

Authors:  Yoshio Shimojima; Hiroshi Morita; Sachio Kobayashi; Yo-ichi Takei; Shu-ichi Ikeda
Journal:  J Neurol       Date:  2008-05-20       Impact factor: 4.849

Review 2.  Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP).

Authors:  Yukio Ando
Journal:  Med Mol Morphol       Date:  2005-09       Impact factor: 2.309

3.  The amyloidoses: clinical features, diagnosis and treatment.

Authors:  Kelty R Baker; Lawrence Rice
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Jul-Sep

Review 4.  Transthyretin-related familial amyloidotic polyneuropathy-Progress in Kumamoto, Japan (1967-2010)-.

Authors:  Shukuro Araki; Yukio Ando
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

5.  Beyond genetic factors in familial amyloidotic polyneuropathy: protein glycation and the loss of fibrinogen's chaperone activity.

Authors:  Gonçalo da Costa; Ricardo A Gomes; Ana Guerreiro; Élia Mateus; Estela Monteiro; Eduardo Barroso; Ana V Coelho; Ana Ponces Freire; Carlos Cordeiro
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

Review 6.  Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis.

Authors:  Teresa Coelho; Giampaolo Merlini; Christine E Bulawa; James A Fleming; Daniel P Judge; Jeffery W Kelly; Mathew S Maurer; Violaine Planté-Bordeneuve; Richard Labaudinière; Rajiv Mundayat; Steve Riley; Ilise Lombardo; Pedro Huertas
Journal:  Neurol Ther       Date:  2016-02-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.